US20030170211A1 - Invasive bacterial vectors for expressing alphavirus replicons - Google Patents
Invasive bacterial vectors for expressing alphavirus replicons Download PDFInfo
- Publication number
- US20030170211A1 US20030170211A1 US10/357,095 US35709503A US2003170211A1 US 20030170211 A1 US20030170211 A1 US 20030170211A1 US 35709503 A US35709503 A US 35709503A US 2003170211 A1 US2003170211 A1 US 2003170211A1
- Authority
- US
- United States
- Prior art keywords
- gene
- antigen
- delivery system
- animal
- hiv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000710929 Alphavirus Species 0.000 title claims abstract description 56
- 230000001580 bacterial effect Effects 0.000 title claims abstract description 47
- 239000013598 vector Substances 0.000 title abstract description 9
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 114
- 239000000427 antigen Substances 0.000 claims abstract description 75
- 108091007433 antigens Proteins 0.000 claims abstract description 74
- 102000036639 antigens Human genes 0.000 claims abstract description 74
- 238000000034 method Methods 0.000 claims abstract description 62
- 230000014509 gene expression Effects 0.000 claims abstract description 60
- 241000894006 Bacteria Species 0.000 claims abstract description 57
- 241001465754 Metazoa Species 0.000 claims abstract description 49
- 210000004102 animal cell Anatomy 0.000 claims abstract description 36
- 230000002238 attenuated effect Effects 0.000 claims abstract description 31
- 239000012634 fragment Substances 0.000 claims abstract description 29
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 27
- 230000028993 immune response Effects 0.000 claims abstract description 11
- 230000001939 inductive effect Effects 0.000 claims abstract description 9
- 108020004414 DNA Proteins 0.000 claims description 50
- 230000035772 mutation Effects 0.000 claims description 38
- 150000007523 nucleic acids Chemical class 0.000 claims description 31
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 27
- 230000000890 antigenic effect Effects 0.000 claims description 22
- 241000607768 Shigella Species 0.000 claims description 16
- 241001167018 Aroa Species 0.000 claims description 11
- 101100491986 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) aromA gene Proteins 0.000 claims description 11
- 230000003321 amplification Effects 0.000 claims description 11
- 101150037081 aroA gene Proteins 0.000 claims description 11
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 11
- 230000003071 parasitic effect Effects 0.000 claims description 11
- 244000052613 viral pathogen Species 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 241000607142 Salmonella Species 0.000 claims description 10
- 101150102858 aroD gene Proteins 0.000 claims description 10
- 101150040872 aroE gene Proteins 0.000 claims description 10
- 101150108612 aroQ gene Proteins 0.000 claims description 10
- 244000052769 pathogen Species 0.000 claims description 10
- 244000052616 bacterial pathogen Species 0.000 claims description 7
- 230000001363 autoimmune Effects 0.000 claims description 6
- 101150007310 htrA gene Proteins 0.000 claims description 5
- 230000001717 pathogenic effect Effects 0.000 claims description 5
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 claims description 4
- 241000607762 Shigella flexneri Species 0.000 claims description 4
- 241000147000 Shigella flexneri 2a Species 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 101150033532 virG gene Proteins 0.000 claims 5
- 108091026890 Coding region Proteins 0.000 claims 4
- 108091035707 Consensus sequence Proteins 0.000 claims 4
- 101150107204 asd gene Proteins 0.000 claims 4
- 108700026220 vif Genes Proteins 0.000 claims 4
- 238000002054 transplantation Methods 0.000 claims 2
- 230000004957 immunoregulator effect Effects 0.000 abstract description 11
- 108020005544 Antisense RNA Proteins 0.000 abstract description 8
- 108090000994 Catalytic RNA Proteins 0.000 abstract description 8
- 102000053642 Catalytic RNA Human genes 0.000 abstract description 8
- 239000003184 complementary RNA Substances 0.000 abstract description 8
- 108091092562 ribozyme Proteins 0.000 abstract description 8
- 239000003795 chemical substances by application Substances 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 7
- 229940124597 therapeutic agent Drugs 0.000 abstract description 7
- 229960005486 vaccine Drugs 0.000 abstract description 7
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 6
- 230000004936 stimulating effect Effects 0.000 abstract description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 25
- 210000001519 tissue Anatomy 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 18
- 210000000805 cytoplasm Anatomy 0.000 description 10
- 230000003612 virological effect Effects 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 8
- 241000186781 Listeria Species 0.000 description 7
- 241000710961 Semliki Forest virus Species 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 108020004511 Recombinant DNA Proteins 0.000 description 5
- -1 rfb Chemical class 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 241000712461 unidentified influenza virus Species 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- 241000588722 Escherichia Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 241000606701 Rickettsia Species 0.000 description 4
- 108091027544 Subgenomic mRNA Proteins 0.000 description 4
- 108700005077 Viral Genes Proteins 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 206010010144 Completed suicide Diseases 0.000 description 3
- 241000186779 Listeria monocytogenes Species 0.000 description 3
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 3
- 241000224016 Plasmodium Species 0.000 description 3
- 108700005078 Synthetic Genes Proteins 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 102000003425 Tyrosinase Human genes 0.000 description 3
- 108060008724 Tyrosinase Proteins 0.000 description 3
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000005030 transcription termination Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 101100404144 Bacillus subtilis (strain 168) nasD gene Proteins 0.000 description 2
- 241000588832 Bordetella pertussis Species 0.000 description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000011632 Caseins Human genes 0.000 description 2
- 108010076119 Caseins Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010066919 Epidemic polyarthritis Diseases 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 241000713800 Feline immunodeficiency virus Species 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 2
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 2
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 241000589248 Legionella Species 0.000 description 2
- 208000007764 Legionnaires' Disease Diseases 0.000 description 2
- 241000222722 Leishmania <genus> Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000713333 Mouse mammary tumor virus Species 0.000 description 2
- 241000186359 Mycobacterium Species 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- 241000710942 Ross River virus Species 0.000 description 2
- 241000702670 Rotavirus Species 0.000 description 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
- 241000242679 Schistosoma bovis Species 0.000 description 2
- 241000242677 Schistosoma japonicum Species 0.000 description 2
- 241000607760 Shigella sonnei Species 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 102000003848 Uteroglobin Human genes 0.000 description 2
- 108090000203 Uteroglobin Proteins 0.000 description 2
- 241000607598 Vibrio Species 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 101150044129 nirB gene Proteins 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 101150028857 phoP gene Proteins 0.000 description 2
- 101150114864 plcA gene Proteins 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 229940115939 shigella sonnei Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 235000021247 β-casein Nutrition 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 108010083528 Adenylate Cyclase Toxin Proteins 0.000 description 1
- 241000607534 Aeromonas Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000009366 Alpha-s1 casein Human genes 0.000 description 1
- 108050000244 Alpha-s1 casein Proteins 0.000 description 1
- 241000415078 Anemone hepatica Species 0.000 description 1
- 101710203310 Apical membrane antigen 1 Proteins 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 241000223836 Babesia Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 108700003860 Bacterial Genes Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000606660 Bartonella Species 0.000 description 1
- 241000238678 Boophilus Species 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100439426 Bradyrhizobium diazoefficiens (strain JCM 10833 / BCRC 13528 / IAM 13628 / NBRC 14792 / USDA 110) groEL4 gene Proteins 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 241000244036 Brugia Species 0.000 description 1
- 241000244038 Brugia malayi Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241000588923 Citrobacter Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000724252 Cucumber mosaic virus Species 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 101100425816 Dictyostelium discoideum top2mt gene Proteins 0.000 description 1
- 241000243990 Dirofilaria Species 0.000 description 1
- 241000223924 Eimeria Species 0.000 description 1
- 101100315734 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) uapA gene Proteins 0.000 description 1
- 241000224431 Entamoeba Species 0.000 description 1
- 241000224432 Entamoeba histolytica Species 0.000 description 1
- 101001095863 Enterobacteria phage T4 RNA ligase 1 Proteins 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000186811 Erysipelothrix Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 101710093554 Galactose-specific lectin Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 241000224466 Giardia Species 0.000 description 1
- 101710178393 Globin-like protein Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 241000665848 Isca Species 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 101710164436 Listeriolysin O Proteins 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 1
- VZUNGTLZRAYYDE-UHFFFAOYSA-N N-methyl-N'-nitro-N-nitrosoguanidine Chemical compound O=NN(C)C(=N)N[N+]([O-])=O VZUNGTLZRAYYDE-UHFFFAOYSA-N 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 241000316848 Rhodococcus <scale insect> Species 0.000 description 1
- 101150010882 S gene Proteins 0.000 description 1
- 241000242678 Schistosoma Species 0.000 description 1
- 241000242680 Schistosoma mansoni Species 0.000 description 1
- 101100406769 Serratia liquefaciens phlA gene Proteins 0.000 description 1
- 241001353427 Shigella flexneri Y Species 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 101100309436 Streptococcus mutans serotype c (strain ATCC 700610 / UA159) ftf gene Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
- 241000243796 Trichostrongylus colubriformis Species 0.000 description 1
- 102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 1
- 108700015934 Triose-phosphate isomerases Proteins 0.000 description 1
- 102000005937 Tropomyosin Human genes 0.000 description 1
- 108010030743 Tropomyosin Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 241000244002 Wuchereria Species 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 201000008680 babesiosis Diseases 0.000 description 1
- 210000003578 bacterial chromosome Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 101150018266 degP gene Proteins 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940007078 entamoeba histolytica Drugs 0.000 description 1
- 230000000688 enterotoxigenic effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 101150077981 groEL gene Proteins 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 101150006815 icsA gene Proteins 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 101150089729 iscA gene Proteins 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 108010002832 murein transglycosylase Proteins 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000002276 neurotropic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000006849 nucleocytoplasmic transport Effects 0.000 description 1
- 101150091444 ompR gene Proteins 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 108010021711 pertactin Proteins 0.000 description 1
- 101150086617 phoQ gene Proteins 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 1
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 101150106872 rpoH gene Proteins 0.000 description 1
- 102200024899 rs121918123 Human genes 0.000 description 1
- 101150025220 sacB gene Proteins 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 101150047061 tag-72 gene Proteins 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 101150082896 topA gene Proteins 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000006490 viral transcription Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 101150075472 ycf27 gene Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention is directed to a bacterial delivery system for delivering alphavirus replicon DNA into an animal or animal cells, the replicon encoding a heterologous gene to be expressed in the animal or the animal cells.
- the bacteria are invasive bacteria or attenuated invasive bacteria engineered to contain a DNA vector that encodes the alphavirus replicon in a eukaryotic expression cassette.
- primary transcription of the DNA vector is driven by the eukaryotic expression vector and produces an alphavirus replicon RNA which is transported the cytoplasm. That RNA is transcribed and translated to express the heterologous gene encoded in the alphavirus replicon.
- the heterologous gene may encode an antigen, a therapeutic agent, an immunoregulatory agent, an anti-sense RNA, a catalytic RNA, a protein, a peptide or any other molecule desired for delivery to an animal or animal cell.
- the heterologous gene encodes an antigen useful as a vaccine for HIV.
- the invention provides methods of introducing and expressing the heterologous gene, methods of stimulating or inducing an immune response and vaccines therefor.
- the eukaryotic expression cassette controlled expression of the primary nuclear transcription of the SFV replicon.
- This SFV replicon transcript encoding the heterologous antigen, was transported to the cytoplasm and amplified by the self-encoded SFV replicase complex.
- the amplified RNA replicon lead to high level production of an mRNA encoding the heterologous antigen.
- Polo and his group Polyo et al.. (1998) Nature Biotechnology 16:517-518; Hariharan et al.. (1998) J. Virol. 72:950-958]. Both groups found strong immune responses could be induced using small amounts of input plasmid DNA. Although this method allows greater expression from the input DNA vector, the method still has the disadvantages associated with parenteral delivery.
- a method to deliver DNA to animals that overcomes the disadvantages of conventional delivery methods is by administering attenuated, invasive bacteria containing a bacterial DNA vector having a eukaryotic expression cassette encoding the gene to be expressed.
- U.S. Pat. No. 5,877,159 to Powell et al.. describes live bacteria that can invade animal cells without establishing a productive infection or causing disease to thereby introduce a eukaryotic expression cassette encoding an antigen capable of being expressed by the animal cells. While this method allows delivery of the DNA vaccine to mucosal surfaces, including easy administration, a concern for vaccine delivery in developing countries, it does not have the advantage of providing amplifiable mRNA encoding the gene of interest.
- the present invention combines use of a live attenuated invasive bacteria with eukaryotic expression cassettes encoding an alphavirus replicon to provide improved bacterial delivery systems to deliver a heterologous gene, and preferably a gene encoding an antigen, to an animal.
- Such systems have the advantages of both bacterial delivery systems and alphavirus replicon vectors and are efficacious, cost effective, and safe.
- the bacterial delivery systems of the invention are particularly useful for delivering DNA for gene therapy and vaccinations.
- one embodiment is directed to a bacterial delivery system which comprises a live invasive bacteria or attenuated, invasive bacteria containing a DNA comprising a eukaryotic expression cassette operably linked to an alphavirus replicon DNA capable of amplification in animal cells, wherein the alpha virus replicon DNA comprises an alphavirus replicon comprises nucleic acid sequences operably linked to a heterologous nucleic acid sequence to control expression thereof.
- the heterologous nucleic acid sequence can encode an antigen, an antigenic fragment of a protein, a therapeutic agent, an immunoregulatory agent, an anti-sense RNA, a catalytic RNA, a protein, a peptide or any other molecule encodable by DNA and desired for delivery to an animal or animal cell.
- the heterologous nucleic acid sequences can be obtained from a virus selected from the group consisting of influenza virus, respiratory syncytial virus, HPV, HBV, HCV, HIV, HSV, FeLV, FIV, HTLV-I, HTLV-II, and CMV. Such viral sequences can encode one or more viral genes or antigenic fragments thereof.
- the heterologous nucleotide sequence can encode a cytokine, an interleukin, erythropoietin or other immunostimulatory or immunoregulatory protein.
- Another embodiment of this invention is directed to a method for introducing and expressing a gene in an animal comprising infecting said animal with live invasive bacteria, wherein said bacteria contain a DNA comprising a eukaryotic expression cassette, wherein said cassette expresses an alphavirus replicon RNA capable of amplification in cells of said animal, wherein said RNA encodes a heterologous gene product, and wherein said gene product is expressed in said animal.
- the method is applicable to deliver genes encoding an antigen, an antigenic protein fragment, a therapeutic agent, an immunoregulatory agent, an anti-sense RNA, a catalytic RNA, a protein, a peptide or any other molecule encodable by DNA and desired for delivery to an animal or an animal cell.
- Another aspect of the invention provides a method for inducing an immune response in an animal which comprises infecting said animal live attenuated invasive bacteria, wherein said bacteria contain one or more DNAs comprising a eukaryotic expression cassette, wherein said cassette expresses an alphavirus replicon RNA capable of amplification in said animal, wherein said RNA encodes an antigen, and wherein said antigen is expressed at a level sufficient to stimulate an immune response to said antigen.
- the antigen is derived from a virus
- Yet another aspect of the invention relates to a method for introducing and expressing a gene in animal cells comprising (a) infecting said animal cells with live invasive bacteria, wherein the bacteria contain one or more DNAs comprising a eukaryotic expression cassette, wherein said cassette expresses an alphavirus replicon RNA capable of amplification in said animal cells and wherein said RNA encodes a heterologous gene product; and (b) culturing those cells under conditions sufficient to express the gene product.
- invasive bacteria are bacteria that are capable of delivering eukaryotic expression cassettes to animal cells or animal tissue.
- Intra bacteria include bacteria that are naturally capable of entering the cytoplasm or nucleus of animal cells, as well as bacteria that are genetically engineered to enter the cytoplasm or nucleus of animal cells or cells in animal tissue.
- attenuated, invasive bacteria are invasive bacteria as defined herein which are capable of infecting an animal host without establishing a productive infection and/or causing disease in the infected host. Thus, at most an attenuated bacterial strain may cause a self-limiting, clinically-insignificant infection.
- Attenuated bacteria of the invention can be prepared by methods known in the art. For example, attenuating mutations can be introduced into bacterial pathogens using non-specific mutagenesis either chemically, using agents such as N-methyl-N′-nitro-N-nitrosoguanidine, or using recombinant DNA techniques; classic genetic techniques, such as Tn10 mutagenesis, P22-mediated transduction, lambda-phage mediated crossover, and conjugational transfer; or site-directed mutagenesis using recombinant DNA techniques. Recombinant DNA techniques are preferable. Examples of such attenuating mutations include, but are not limited to:
- auxotrophic mutations such as aro (Hoiseth et al., Nature, 291:238-239 (1981)), gua (McFarland et al., Microbiol. Path., 3:129-141 (1987)), and (Park et al.., J. Bact., 170:3725-3730 (1988), thy (Nnalue et al., Infect. Immun., 55:955-962 (1987)), and asd (Curtiss, supra) mutations;
- the attenuating mutations can be either constitutively expressed or under the control of inducible promoters, such as the temperature sensitive heat shock family of promoters (Neidhardt et al., 1984, supra), or the anaerobically induced nirB promoter (Harborne et al., Mol. Micro., 6:2805-2813 (1992)) or repressible promoters, such as uapA (Gorfinkiel et al., J. Biol. Chem., 268:23376-23381 (1993)) or gcv (Stauffer et al., J. Bact., 176:6159-6164 (1994)).
- inducible promoters such as the temperature sensitive heat shock family of promoters (Neidhardt et al., 1984, supra), or the anaerobically induced nirB promoter (Harborne et al., Mol. Micro., 6:2805-2813 (1992)
- the particular naturally occurring invasive bacteria (or attenuated, invasive bacteria) employed in the present invention is not critical thereto.
- One of ordinary skill in the art can readily determine which bacterial strains are appropriate for use with the animal or animal cells intended to be infected based on the animal's or cells' susceptibility to infection by different bacterial species.
- Examples of such naturally-occurring invasive bacteria include, but are not limited to, Salmonella spp. Shigella spp., Listeria spp., Rickettsia spp. and enteroinvasive Escherichia coli. Any of these strains can be attenuated if needed using known methods.
- Shigella strains which can be employed in the present invention include, but are not limited to, Shigella flexneri 2a (ATCC No. 29903), Shigella sonnei (ATCC No. 29930), and Shigella disenteriae (ATCC No. 13313).
- An attenuated Shigella strain such as Shigella flexneri 2a 2457T ⁇ aroA ⁇ virG mutant CVD 1203 (Noriega et al., supra), Shigella flexneri M90T ⁇ icsA mutant (Goldberg et al., Infect.
- Shigella flexneri Y SFL114 aroD mutant (Karnell et al., Vacc., 10:167-174 (1992)), and Shigella flexneri ⁇ aroA ⁇ aroD mutant (Verma et al., Vacc., 9:6-9 (1991)) are preferably employed in the present invention.
- new attenuated Shigella spp. strains can be constructed by introducing an attenuating mutation either singularly or in conjunction with one or more additional attenuating mutations.
- Listeria strains which can be employed in the present invention include Listeria monocytogenes (ATCC No. 15313). Attenuated Listeria strains, such as L. monocytogenes ⁇ actA mutant (Brundage et al., supra) or L. monocytogenes ⁇ plcA (Camilli et al., J. Exp. Med., 173:751-754 (1991)) are preferably used in the present invention. Alternatively, new attenuated Listeria strains can be constructed by introducing one or more attenuating mutations as described for Shigella spp. above.
- Rickettsia strains which can be employed in the present invention include Ricketsia rickettsiae (ATCC Nos. VR149 and VR891), Ricketsia prowaseckii (ATCC No. VR233), Ricketsia tsutsugamuchi (ATCC Nos. VR312, VR150 and VR609), Ricketsia mooseri (ATCC No. VR144), Ricketsia sibirica (ATCC No. VR151), and Rochalimaea quitana (ATCC No. VR358).
- Attenuated Ricketsia strains are preferably used in the present invention and can be constructed by introducing one or more attenuating mutations as described for Shigella spp. above.
- enteroinvasive Escherichia strains which can be employed in the present invention include Escherichia coli strains 4608-58, 1184-68, 53638-C-17, 13-80, and 6-81 (Sansonetti et aL, Ann. Microbiol. (Inst. Pasteur), 132A:351-355 (1982)).
- Attenuated enteroinvasive Escherichia strains are preferably used in the present invention and can be constructed by introducing one or more attenuating mutations as described for Shigella spp. above.
- Examples of additional bacteria which can be genetically engineered to be invasive include, but are not limited to, Yersinia spp., Escherichia spp., Klebsiella spp., Bordetella spp., Neisseria spp., Aeromonas spp., Franciesella spp., Corynebacterium spp., Citrobacter spp., Chlamydia spp., Hemophilus spp., Brucella spp., Mycobacterium spp., Legionella spp., Rhodococcus spp., Pseudomonas spp., Helicobacter spp., Salmonella spp., Vibrio spp., Bacillus spp., and Erysipelothrix spp.
- These organisms can be engineered to mimic the invasion properties of Shigella spp., Listeria spp., Rickettsia spp., or enteroinvasive E. coli spp. by inserting genes that enable them to access the cytoplasm of an animal cell. Examples of useful strains from these bacteria are found in U.S. Pat. No. 5,877,159 and also include Mycobacterium bovis BCG.
- genes include the invasive proteins of Shigella, hemolysin or the invasion plasmid of Escherichia, or listeriolysin O of Listeria, as such techniques are known to result in strains that are capable of entering the cytoplasm of infected animal cells (Formal etal., Infect. immun., 46:465 (1984); Bielecke etal., Nature, 345:175-176 (1990); Small et al., In: Microbiology-1986, pages 121-124, Levine et al., Eds., American Society for Microbiology, Washington, D.C. (1986); and Zychlinsky et al., Molec.
- genes are not limited to bacterial genes, and include viral genes, such as influenza virus hemagglutinin HA-2 which promotes endosmolysis (Plank et al., J. Biol. Chem., 269:12918-12924 (1994)).
- the above invasive genes can be introduced into the target strain using chromosome or plasmid mobilization (Miller, A Short Course in Bacterial Genetics, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1992); Bothwell et al., supra; and Ausubel et al., supra), bacteriophage-mediated transduction (de Boer, supra; Miller, supra; and Ausubel et al., supra), or chemical (Bothwell et al., supra; Ausubel et al., supra; Felgner et al., supra; and Farhood, supra), electroporation (Bothwel et al., supra; Ausubel et al., supra; and Sambrook, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.) and physical transformation techniques (Johnston et al., supra; and Bothwell, supra).
- the genes can be incorporated on bacteriophage (de Boer et al., Cell, 56:641-649 (1989)), plasmids vectors (Curtiss et al., supra) or spliced into the chromosome (Hone et al., supra) of the target strain.
- the bacteria for use in the invention can be modified to increase their ability to infect mucosal surfaces and tissues in an animal Such modifications permit the bacteria to circumvent natural host barriers. Methods for constructing such bacteria are described in U.S. Pat. No. 5,877,159.
- the invasive or attenuated invasive bacteria contain a DNA comprising a eukaryotic expression cassette operably linked to an alphavirus replicon DNA.
- a eukaryotic expression cassette is usually in the form of a plasmid which contains elements needed for transcription of the alphavirus replicon DNA and transport from the nucleus into the cytoplasm.
- RNA polymerase II cassettes provide the needed control and regulatory elements.
- the elements for transcription include but are not limited to promoters active in eukaryotic cells, enhancers, transcription termination signals including polyadenylation signals or polyA tracts, elements to facilitate nucleocytoplasmic transport, elements to facilitate processing of the 3 ′ alphavirus replicon RNA into an authentic virus-like RNA 3′ ends and the like.
- the particular eukaryotic cassette employed in the present invention is not critical thereto, and can be selected from, e.g., any of the many commercially available cassettes, such as pCEP4 or pRc/RSV obtained from Invitrogen Corporation (San Diego, Calif.), pXT1, pSG5, pPbac or pMbac obtained from Stratagene (La Jolla, Calif.), pPUR or pMAM obtained from ClonTech (Palo Alto, Calif.), and pSV.beta.-gal obtained from Promega Corporation (Madison, Wis.), or synthesized either de novo or by adaptation of a publically or commercially available eukaryotic expression system.
- cassettes such as pCEP4 or pRc/RSV obtained from Invitrogen Corporation (San Diego, Calif.), pXT1, pSG5, pPbac or pMbac obtained from Stratagene (La Jolla, Calif.), pPUR or
- the individual elements within the eukaryotic expression cassette can be derived from multiple sources and may be selected to confer specificity in sites of action or longevity of the cassettes in the recipient cell. Such manipulation of the eukaryotic expression cassette can be done by any standard molecular biology approach.
- tissue-specific promoters include, but are not limited to, ⁇ S1- and ⁇ -casein promoters which are specific for mammary tissue (Platenburg et al., Trans.
- cell specific enhancer sequences can be used to control expression, for example human neurotropic papovirus JCV enhancer regulates viral transcription in glial cells alone (Remenick et al., J. Virol., 65:5641-5646 (1991)).
- HRE hormone responsive element
- Yet another way to control tissue specific expression is to use a hormone responsive element (HRE) to specify which cell lineages a promoter will be active in, for example, the MMTV promoter requires the binding of a hormone receptor, such as progesterone receptor, to an upstream HRE before it is activated (Beato, FASEB J., 5:2044-2051 (1991); and Truss et al., J. Steroid Biochem. Mol. Biol., 41:241-248 (1992)).
- HRE hormone responsive element
- Suitable transcription termination elements include the SV 40 transcription termination region and terminators derived therefrom.
- the bacteria of the bacterial delivery systems can contain one or more eukaryotic expression cassettes operably linked to an alphavirus replicon.
- Such cassettes can be provided on the same or different plasmids or DNA molecules contained in the bacteria.
- Alphavirus are from the Togavirus family and are well known in the art. There are 26 known viruses and virus subtype classified using the hemagglutination assay. See, e.g., U.S. Pat. No. 5,843,723 for list of the many of the alphaviruses.
- the commonly studied alphaviruses include Sindbis, SFV, Venezuelan equine encephalitis virus (VEE) and Ross River virus.
- VEE Venezuelan equine encephalitis virus
- Ross River virus The morphogenesis of the viruses is fairly uniform and the virions are small enveloped 60-65 nm particles of positive strand RNA.
- the genomic RNA (49S RNA) of alphaviruses is approximately 11-12 kb in length, and contains a 5′ cap and a 3′ polyadenylate tail. Infectious enveloped virus is produced by assembly of the viral nucleocapsid proteins onto genomic RNA in the cytoplasm, and budding through the cell membrane embedded with viral-encoded glycoproteins.
- the genomic 49S RNA serves as template for synthesis of a complementary negative strand.
- the negative strand in turn serves as template for full-length genomic RNA and for an internally initiated positive-strand 26S subgenomic RNA.
- the nonstructural proteins are translated from the genomic RNA.
- Alphaviral structural proteins are translated from the subgenomic 26S RNA. All viral genes are expressed as polyproteins and processed into individual proteins by proteolytic cleavage post-translation.
- an “alphavirus replicon” of the present invention is used interchangeably to refer to RNA or DNA comprising those portions of the alphavirus genome RNA essential for transcription and export of a primary RNA transcript from the cell nucleus to the cytoplasm, for cytoplasmic amplification of the transported RNA and for subgenomic RNA expression of a heterologous nucleic acid sequence.
- the replicon encodes and expresses those non-structural proteins needed for cytoplasmic amplification of the alphavirus RNA and expression of the subgenomic RNA. It is further preferable that the alphavirus replicon can not be encapsidated to produce alphavirus particles or virions.
- alphavirus replicons of the invention are capable of being transcribed from a eukaryotic expression cassette and processed into RNA molecules with authentic alphavirus-like 5′ and 3′ ends.
- Alphavirus replicons and expression vectors containing them are well known in the art and many vectors containing a wide range of alphavirus replicons have been described. Examples of such replicons can be found, e.g., in U.S. Pat. Nos. 5,739,026; 5,766,602; 5,789,245; 5,792,462; 5,814,482; and 5,843,723 and in Polo, supra, and Berglund, supra. While many of the features of these alphavirus replicons are useful for the present invention not all of them are essential for the reasons set forth above.
- Alphavirus replicons can be prepared from any alphavirus or any mixture of alphavirus nucleic acid sequences.
- the preferred alphavirus replicons are derived from Sindbis virus, SFV, VEE or Ross River virus.
- alphavirus replicons can be incorporated as DNA into eukaryotic expression cassettes using recombinant DNA techniques conventional in the art.
- the alphavirus replicon comprises a nucleic acid sequence operably linked to a heterologous nucleic acid sequence to control expression thereof.
- the heterologous nucleic acid sequence can encode an antigen, an antigenic fragment of a protein, a therapeutic agent, an immunoregulatory agent, an anti-sense RNA, a catalytic RNA, a protein, a peptide or any other molecule encodable by DNA and desired for delivery to an animal or animal cell.
- the heterologous nucleic acid sequences can be obtained from a virus selected from the group consisting of influenza virus, respiratory syncytial virus, HPV, HBV, HCV, HIV, HSV, FeLV, FIV, HTLV-I, HTLV-II, and CMV.
- viral sequences can encode one or more viral genes or antigenic fragments thereof.
- the heterologous nucleotide sequence can also encode a cytokine, an interleukin, erythropoietin or other immunostimulatory or immunoregulatory protein.
- heterologous refers to the relationship between the source of the alphavirus replicon and the source of the heterologous nucleic acid sequence.
- the heterologous nucleic acid gene will not be encode an alphavirus gene but could encode a gene that is either foreign or endogenous to the animal cells that have been infected with the bacterial delivery system of the invention.
- “foreign gene or nucleic acid sequence” means a gene or a nucleic acid sequence encoding a protein or fragment thereof or anti-sense RNA or catalytic RNA, which is foreign to the recipient animal cell or tissue, such as a vaccine antigen, immunoregulatory agent, or therapeutic agent.
- An “endogenous gene or nucleic acid sequence” means a gene or a nucleic acid sequence encoding a protein or part thereof or anti-sense RNA or catalytic RNA which is naturally present in the recipient animal cell or tissue.
- the antigen may be a protein or antigenic fragment thereof from viral pathogens, bacterial pathogens, and parasitic pathogens.
- the antigen may be a synthetic gene, constructed using recombinant DNA methods, which encode antigens or parts thereof from viral, bacterial, parasitic pathogens. These pathogens can be infectious in humans, domestic animals or wild animal hosts.
- the antigen can be any molecule that is expressed by any viral, bacterial, parasitic pathogen prior to or during entry into, colonization of, or replication in their animal host.
- Single or multiple eukaryotic expression cassettes can be delivered that express any combination of viral, bacterial, parasitic antigens, or synthetic genes encoding all or parts or any combination of viral, bacterial, parasitic antigens.
- the viral pathogens from which the viral antigens are derived, include, but are not limited to, Orthomyxoviruses, such as influenza virus; Retroviruses, such as RSV and SIV, Herpesviruses, such as EBV; CMV or herpes simplex virus; Lentiviruses, such as human immunodeficiency virus; Rhabdoviruses, such as rabies; Picornoviruses, such as poliovirus; Poxviruses, such as vaccinia; Rotavirus; and Parvoviruses.
- Orthomyxoviruses such as influenza virus
- Retroviruses such as RSV and SIV
- Herpesviruses such as EBV
- Lentiviruses such as human immunodeficiency virus
- Rhabdoviruses such as rabies
- Picornoviruses such as poliovirus
- Poxviruses such as vaccinia
- Rotavirus Rota
- protective antigens of viral pathogens include the HIV antigens Nef, p24, gp 120, gp41, gp 160, Tat, Rev, and Pol et al., Nature, 313:277-280 (1985)) and T cell and B cell epitopes of gp120 (Palker et al., J. Immunol., 142:3612-3619 (1989)); the hepatitis B surface antigen (Wu et al., Proc. Natl. Acad. Sci., USA, 86:4726-4730 (1989)); rotavirus antigens, such as VP4 (Mackow et al., Proc. Natl. Acad.
- influenza virus antigens such as hemagglutinin or nucleoprotein (Robinson et al.., Supra; Webster et al., Supra) and herpes simplex virus thymidine kinase (Whitley et al., In: New Generation Vaccines, pages 825-854).
- influenza virus antigens such as hemagglutinin or nucleoprotein (Robinson et al.., Supra; Webster et al., Supra) and herpes simplex virus thymidine kinase (Whitley et al., In: New Generation Vaccines, pages 825-854).
- the antigens can be from any structural, accessory or regulatory gene, and includes combinations or chimeras of such genes in multiple or single alphavirus replicons.
- the bacterial pathogens from which the bacterial antigens are derived, include but are not limited to, Mycobacterium spp., Helicobacter pylori, Salmonella spp., Shigella spp., E. coli, Rickettsia spp., Listeria spp., Legionella pneumoniae, Pseudomonas spp., Vibrio spp., and Borellia burgdorferi.
- protective antigens of bacterial pathogens include the Shigella sonnei form 1 antigen (Formal et al., Infect. Immun., 34:746-750 (1981)); the O-antigen of V. cholerae Inaba strain 569B (Forrest et al., J. Infect. Dis., 159:145-146 (1989); protective antigens of enterotoxigenic E. coli, such as the CFA/I fimbrial antigen (Yamamoto et al., Infect.
- the parasitic pathogens from which the parasitic antigens are derived, include but are not limited to, Plasmodium spp., Trypanosome spp., Giardia spp., Boophilus spp., Babesia spp., Entamoeba spp., Eimeria spp., Leishmania spp., Schistosome spp., Brugia spp., Fascida spp., Dirofilaria spp., Wuchereria spp., and Onchocerea spp.
- Examples of protective antigens of parasitic pathogens include the circumsporozoite antigens of Plasmodium spp. (Sadoff et al., Science, 240:336-337 (1988)), such as the circumsporozoite antigen of P. bergerii or the circumsporozoite antigen of P. falciparum; the merozoite surface antigen of Plasmodium spp. (Spetzler et al., Int. J. Pept. Prot. Res., 43:351-358 (1994)); the galactose specific lectin of Entamoeba histolytica (Mann et al., Proc. Natl. Acad.
- the live invasive bacteria can also deliver eukaryotic expression cassettes encoding a therapeutic agent to animal cells or animal tissue.
- the eukaryotic expression cassettes can encode tumor-specific, transplant, or autoimmune antigens or parts thereof.
- the eukaryotic expression cassettes can encode synthetic genes, which encode tumor-specific, transplant, or autoimmune antigens or parts thereof. Examples of tumor specific antigens include prostate specific antigen (Gattuso et al., Human Pathol., 26:123-126 (1995)), TAG-72 and CEA (Guadagni et al., Int. J. Biol.
- autoimmune antigens include IAS .beta. chain (Topham et al., Proc. Natl. Acad. Sci., USA, 91:8005-8009 (1994)). Vaccination of mice with an 18 amino acid peptide from IAS beta. chain has been demonstrated to provide protection and treatment to mice with experimental autoimmune encephalomyelitis (Topham et al., supra).
- live invasive bacteria can deliver eukaryotic expression cassettes encoding immunoregulatory molecules.
- immunoregulatory molecules include, but are not limited to, growth factors, such as M-CSF, GM-CSF; and cytokines, such as IL-2, IL-4, L-5, IL-6, IL-10, IL-12 or IFN-gamma.
- growth factors such as M-CSF, GM-CSF
- cytokines such as IL-2, IL-4, L-5, IL-6, IL-10, IL-12 or IFN-gamma.
- Recently, delivery of cytokines expression cassettes to tumor tissue has been shown to stimulate potent systemic immunity and enhanced tumor antigen presentation without producing a systemic cytokine toxicity (Golumbek et al., Canc. Res., 53:5841-5844 (1993); Golumbek et al., Immun. Res., 12:183-192 (1993); Pardoll, Curr. Opin. Oncol.
- the antisense RNA and catalytic RNA species delivered to animal cells can be targeted against any molecule present within the recipient cell or likely to be present within the recipient cell. These include but are not limited to RNA species encoding cell regulatory molecules, such as interleukin-6 (Mahieu et al., Blood, 84:3758-3765 (1994)), oncogenes such as ras (Kashani-Sabet et al., Antisen. Res. Devel., 2:3-15 (1992)), causative agents of cancer such as human papillomavirus (Steele et al., Canc.
- cell regulatory molecules such as interleukin-6 (Mahieu et al., Blood, 84:3758-3765 (1994)
- oncogenes such as ras
- causative agents of cancer such as human papillomavirus (Steele et al., Canc.
- RNAs can also be targeted at non-transcribed DNA sequences, such as promoter or enhancer regions, or to any other molecule present in the recipient cells, such as but not limited to, enzymes involved in DNA synthesis or tRNA molecules (Scanlon et al., Proc. Natl. Acad. Sci. USA, 88:10591-10595 (1991); and Baier et al., Mol. Immunol., 31:923-932 (1994)).
- live invasive bacteria can also deliver eukaryotic expression cassettes encoding proteins to animal tissue from which they can later be harvested or purified.
- eukaryotic expression cassettes under the control of a mammary specific viral promoter, such as derived from mouse mammary tumor virus (ATCC No. VR731), encoding ⁇ -antitrypsin to mammary tissue of a goat or sheep.
- an invasive bacteria carrying a eukaryotic expression cassette can be introduced to a tissue site such that it would not spread from such a site.
- a strong promoter such as the anaerobic nirB promoter (Harborne et al., supra) which will be switched on within the recipient host tissue.
- the eukaryotic expression cassette of interest can be given to an animal so as to manipulate expression levels or product type.
- This approach obviates the need for specially raised transgenic animals containing tissue specific promoters and having tight control of expression, as is currently the case (Janne et al., Int. J. Biochem., 26:859-870 (1994); Mullins et al., Hyperten., 22:630-633 (1993); and Persuy et al., Eur. J. Bichem., 205:887-893 (1992)).
- single or multiple eukaryotic expression cassettes encoding tumor-specific, transplant, and/or autoimmune antigens can be delivered in any single or multiple combination with eukaryotic expression cassettes encoding immunoregulatory molecules or other proteins.
- the invasive bacteria containing the eukaryotic expression cassette can be used to infect animal cells that are cultured in vitro.
- the animal cells can be further cultured in vitro, and the cells carrying the desired genetic trait can be enriched by selection for or against any selectable marker introduced to the recipient cell at the time of bactofection.
- selectable marker may include antibiotic resistance genes, e.g., hygromycin, or neomycin, selectable cell surface markers, or any other phenotypic or genotypic element introduced or altered by bactofection.
- These in vitro-infected cells or the in vitro-enriched cells can then be introduced into animals intravenously, intramuscularly, intradermally, or intraperitoneally, or by any inoculation route that allows the cells to enter the host tissue.
- the invasive (or invasive, attenuated) bacteria containing the eukaryotic expression cassettes can be introduced to infect the animal by intravenous, intramuscular, intradermal, intraperitoneally, peroral, intranasal, intraocular, intrarectal, intravaginal, oral, immersion and intraurethral inoculation routes.
- the amount of the live invasive (or invasive, attenuated) bacteria of the present invention to be administered will vary depending on the species of the subject, as well as the disease or condition that is being treated. Generally, the dosage employed will be about 10 3 to 10 11 viable organisms, preferably about 10 5 to 10 9 viable organisms. Alternatively, when bactofecting individual cells, the dosage of viable organisms to administered will be at a multiplicity of infection ranging from about 0.1 to 10 6 , preferably about 10 2 to 10 4 .
- the invasive bacteria of the present invention are generally administered along with a pharmaceutically acceptable carrier or diluent.
- diluents include a phosphate buffered saline, buffer for buffering against gastric acid in the stomach, such as citrate buffer (pH 7.0) containing sucrose, bicarbonate buffer (pH 7.0) alone (Levine et al., J. Clin. Invest., 79:888-902 (1987); and Black et al. J. Infect. Dis., 155:1260-1265 (1987)), or bicarbonate buffer (pH 7.0) containing ascorbic acid, lactose, and optionally aspartame (Levine et al., Lancet, II:467-470 (1988)).
- citrate buffer pH 7.0
- bicarbonate buffer pH 7.0
- bicarbonate buffer pH 7.0
- carriers include proteins, e.g., as found in skim milk, sugars, e.g., sucrose, or polyvinylpyrrolidone. Typically these carriers would be used at a concentration of about 0.1-90% (w/v) but preferably at a range of 1-10% (w/v).
- the methods of the invention can be used in mammalian, avian, insect cells and the like.
- the mammalian cells are selected from the group consisting of human, bovine, ovine, porcine, feline, buffalo, canine, goat, equine, donkey, deer, and primate cells.
- the methods of the invention are preferably used in mammals and birds.
- the preferred mammal is a human.
Abstract
The present invention is directed to a bacterial delivery system for delivering alphavirus replicon DNA into an animal or animal cells with the replicon encoding one or more heterologous genes to be expressed in the animal or the animal cells. The bacteria are invasive bacteria or attenuated invasive bacteria engineered to contain a DNA vector that encodes the alphavirus replicon in a eukaryotic expression cassette. The heterologous gene can encode an antigen, a therapeutic agent, an immunoregulatory agent, an anti-sense RNA, a catalytic RNA, a protein, a peptide, an antibody or an antigen-binding fragment of an antibody. In a preferred embodiment, the heterologous gene encodes one or more antigens useful as a vaccine for HIV. In addition to the bacterial delivery system, the invention provides methods of introducing and expressing the heterologous gene(s) in animal or animal cells and methods of stimulating or inducing an immune response.
Description
- This application is a continuation of U.S. Ser. No. 09/697,236 filed Oct. 26, 2000.
- The present invention is directed to a bacterial delivery system for delivering alphavirus replicon DNA into an animal or animal cells, the replicon encoding a heterologous gene to be expressed in the animal or the animal cells. The bacteria are invasive bacteria or attenuated invasive bacteria engineered to contain a DNA vector that encodes the alphavirus replicon in a eukaryotic expression cassette. Upon bacterial infection, primary transcription of the DNA vector is driven by the eukaryotic expression vector and produces an alphavirus replicon RNA which is transported the cytoplasm. That RNA is transcribed and translated to express the heterologous gene encoded in the alphavirus replicon. The heterologous gene may encode an antigen, a therapeutic agent, an immunoregulatory agent, an anti-sense RNA, a catalytic RNA, a protein, a peptide or any other molecule desired for delivery to an animal or animal cell. In a preferred embodiment, the heterologous gene encodes an antigen useful as a vaccine for HIV. In addition to the bacterial delivery system, the invention provides methods of introducing and expressing the heterologous gene, methods of stimulating or inducing an immune response and vaccines therefor.
- There are many applications for delivering DNA to animals or animal cells including for gene therapy of acquired or inherited diseases or conditions, for DNA-based vaccination, for understanding genetic structure and for studying the molecular mechanisms underlying gene expression.
- Successful delivery of DNA to animal tissue has been achieved by cationic liposomes (Watanabe et al., Mol. Reprod. Dev., 38:268-274 (1994)), direct injection of naked DNA into animal muscle tissue (Robinson et al., Vacc., 11:957-960 (1993); Hoffman et al., Vacc., 12:1529-1533; (1994); Xiang et al., Virol., 199:132-140 (1994); Webster et al., Vacc., 12:1495-1498 (1994); Davis et al., Vacc., 12:1503-1509 (1994); and Davis et al., Hum. Molec. Gen., 2:1847-1851 (1993)), and embryos (Naito et al., Mol. Reprod. Dev., 39:153-161 (1994); and Burdon et al., Mol. Reprod. Dev., 33:436-442 (1992)), or intradermal injection of DNA using “gene gun” technology (Johnston et al., supra). A limitation of these techniques is that they only efficiently deliver DNA to parenteral sites. At present, effective delivery of eukaryotic expression cassettes to mucosal tissue has been met with limited success. This is presumably due to poor access to these sites, toxicity of the delivery vehicles or instability of the delivery vehicles when delivered orally.
- For DNA-based vaccination, delivery by injection of naked plasmid DNA has shown potential in mouse models for inducing both humoral and cellular immune responses. However, in larger animals, using DNA delivery for vaccination has been hampered by requiring large amounts of DNA or inducing persistent expression of an antigen with the potential for developing tolerance to the antigen. Berglund reported a strategy for inducing or enhancing an immune response by injecting mice with plasmid DNA containing an alphavirus DNA expression vector having a recombinant Semliki Forest Virus (SFV) replicon in a eukaryotic expression cassette [Berglund et al.. (1998) Nature Biotechnology 16:562-565]. The eukaryotic expression cassette controlled expression of the primary nuclear transcription of the SFV replicon. This SFV replicon transcript, encoding the heterologous antigen, was transported to the cytoplasm and amplified by the self-encoded SFV replicase complex. The amplified RNA replicon lead to high level production of an mRNA encoding the heterologous antigen. Similar results were described by Polo and his group [Polo et al.. (1998) Nature Biotechnology 16:517-518; Hariharan et al.. (1998) J. Virol. 72:950-958]. Both groups found strong immune responses could be induced using small amounts of input plasmid DNA. Although this method allows greater expression from the input DNA vector, the method still has the disadvantages associated with parenteral delivery.
- Alternatively, a method to deliver DNA to animals that overcomes the disadvantages of conventional delivery methods is by administering attenuated, invasive bacteria containing a bacterial DNA vector having a eukaryotic expression cassette encoding the gene to be expressed. For example, U.S. Pat. No. 5,877,159 to Powell et al.. describes live bacteria that can invade animal cells without establishing a productive infection or causing disease to thereby introduce a eukaryotic expression cassette encoding an antigen capable of being expressed by the animal cells. While this method allows delivery of the DNA vaccine to mucosal surfaces, including easy administration, a concern for vaccine delivery in developing countries, it does not have the advantage of providing amplifiable mRNA encoding the gene of interest.
- Accordingly, the present invention combines use of a live attenuated invasive bacteria with eukaryotic expression cassettes encoding an alphavirus replicon to provide improved bacterial delivery systems to deliver a heterologous gene, and preferably a gene encoding an antigen, to an animal. Such systems have the advantages of both bacterial delivery systems and alphavirus replicon vectors and are efficacious, cost effective, and safe. The bacterial delivery systems of the invention are particularly useful for delivering DNA for gene therapy and vaccinations.
- All cited references and patents are incorporated herein in their entirety by reference.
- In accordance with the invention, one embodiment is directed to a bacterial delivery system which comprises a live invasive bacteria or attenuated, invasive bacteria containing a DNA comprising a eukaryotic expression cassette operably linked to an alphavirus replicon DNA capable of amplification in animal cells, wherein the alpha virus replicon DNA comprises an alphavirus replicon comprises nucleic acid sequences operably linked to a heterologous nucleic acid sequence to control expression thereof. The heterologous nucleic acid sequence can encode an antigen, an antigenic fragment of a protein, a therapeutic agent, an immunoregulatory agent, an anti-sense RNA, a catalytic RNA, a protein, a peptide or any other molecule encodable by DNA and desired for delivery to an animal or animal cell. The heterologous nucleic acid sequences can be obtained from a virus selected from the group consisting of influenza virus, respiratory syncytial virus, HPV, HBV, HCV, HIV, HSV, FeLV, FIV, HTLV-I, HTLV-II, and CMV. Such viral sequences can encode one or more viral genes or antigenic fragments thereof. The heterologous nucleotide sequence can encode a cytokine, an interleukin, erythropoietin or other immunostimulatory or immunoregulatory protein.
- Another embodiment of this invention is directed to a method for introducing and expressing a gene in an animal comprising infecting said animal with live invasive bacteria, wherein said bacteria contain a DNA comprising a eukaryotic expression cassette, wherein said cassette expresses an alphavirus replicon RNA capable of amplification in cells of said animal, wherein said RNA encodes a heterologous gene product, and wherein said gene product is expressed in said animal. The method is applicable to deliver genes encoding an antigen, an antigenic protein fragment, a therapeutic agent, an immunoregulatory agent, an anti-sense RNA, a catalytic RNA, a protein, a peptide or any other molecule encodable by DNA and desired for delivery to an animal or an animal cell.
- Another aspect of the invention provides a method for inducing an immune response in an animal which comprises infecting said animal live attenuated invasive bacteria, wherein said bacteria contain one or more DNAs comprising a eukaryotic expression cassette, wherein said cassette expresses an alphavirus replicon RNA capable of amplification in said animal, wherein said RNA encodes an antigen, and wherein said antigen is expressed at a level sufficient to stimulate an immune response to said antigen. In a preferred embodiment the antigen is derived from a virus
- Yet another aspect of the invention relates to a method for introducing and expressing a gene in animal cells comprising (a) infecting said animal cells with live invasive bacteria, wherein the bacteria contain one or more DNAs comprising a eukaryotic expression cassette, wherein said cassette expresses an alphavirus replicon RNA capable of amplification in said animal cells and wherein said RNA encodes a heterologous gene product; and (b) culturing those cells under conditions sufficient to express the gene product.
- As used herein, “invasive bacteria” are bacteria that are capable of delivering eukaryotic expression cassettes to animal cells or animal tissue. “Invasive bacteria” include bacteria that are naturally capable of entering the cytoplasm or nucleus of animal cells, as well as bacteria that are genetically engineered to enter the cytoplasm or nucleus of animal cells or cells in animal tissue. As used herein, “attenuated, invasive bacteria” are invasive bacteria as defined herein which are capable of infecting an animal host without establishing a productive infection and/or causing disease in the infected host. Thus, at most an attenuated bacterial strain may cause a self-limiting, clinically-insignificant infection.
- Attenuated bacteria of the invention can be prepared by methods known in the art. For example, attenuating mutations can be introduced into bacterial pathogens using non-specific mutagenesis either chemically, using agents such as N-methyl-N′-nitro-N-nitrosoguanidine, or using recombinant DNA techniques; classic genetic techniques, such as Tn10 mutagenesis, P22-mediated transduction, lambda-phage mediated crossover, and conjugational transfer; or site-directed mutagenesis using recombinant DNA techniques. Recombinant DNA techniques are preferable. Examples of such attenuating mutations include, but are not limited to:
- (i) auxotrophic mutations, such as aro (Hoiseth et al., Nature, 291:238-239 (1981)), gua (McFarland et al., Microbiol. Path., 3:129-141 (1987)), and (Park et al.., J. Bact., 170:3725-3730 (1988), thy (Nnalue et al., Infect. Immun., 55:955-962 (1987)), and asd (Curtiss, supra) mutations;
- (ii) mutations that inactivate global regulatory functions, such as cya (Curtiss et al., Infect. Immun., 55:3035-3043 (1987) ), crp (Curtiss et al. (1987), supra), phoP/phoQ (Groisman et al., Proc. Natl. Acad. Sci., USA, 86:7077-7081 (1989); and Miller et al., Proc. Natl. Acad. Sci., USA, 86:5054-5058 (1989)), phoPc (Miller et al., J. Bact., 172:2485-2490 (1990)) or ompR (Dorman et al., Infect. Immun., 57:2136-2140 (1989)) mutations;
- (iii) mutations that modify the stress response, such as recA (Buchmeier et al., Mol. Micro., 7:933-936 (1993)), htrA (Johnson et al., Mol. Micro., 5:401-407 (1991)), htpR (Neidhardt et al., Biochem. Biophys. Res. Com., 100:894-900 (1981)), hsp (Neidhardt et al., Ann. Rev. Genet., 18:295-329 (1984)) and groEL (Buchmeier et al., Sci., 248:730-732 (1990)) mutations;
- (iv) mutations in specific virulence factors, such as lsyA (Libby et al., Proc. Natl. Acad. Sci., USA, 91:489-493 (1994)), pag or prg (Miller et al. (1990), supra; and Miller et al. (1989), supra), iscA or virG (d'Hauteville et al., Mol. Micro., 6:833-841 (1992)), plcA (Mengaud et al., Mol. Microbiol., 5:367-72 (1991); Camilli et al., J. Exp. Med, 173:751-754 (1991)), and act (Brundage et al., Proc. Natl. Acad. Sci., USA, 90:11890-11894 (1993)) mutations;
- (v) mutations that affect DNA topology, such as topA (Galan et al., Infect. Immun., 58:1879-1885 (1990)) mutation;
- (vi) mutations that block biogenesis of surface polysaccharides, such as rfb, galE (Hone et al., J. Infect. Dis., 156:164-167 (1987)) or via (Popoff et al., J. Gen. Microbiol., 138:297-304 (1992)) mutations;
- (vii) mutations that modify suicide systems, such as sacB (Recorbet et al., App. Environ. Micro., 59:1361-1366 (1993); Quandt et al., Gene, 127:15-21 (1993)), nuc (Ahrenholtz et al., App. Environ. Micro., 60:3746-3751 (1994)), hok, gef, kil, or phlA (Molin et al., Ann. Rev. Microbiol., 47:139-166 (1993)) mutations;
- (viii) mutations that introduce suicide systems, such as lysogens encoded by P22 (Rennell et al., Virol., 143:280-289 (1985)), lambda murein transglycosylase (Bienkowska-Szewczyk et al., Mol. Gen. Genet., 184:111-114 (1981)) or S-gene (Reader et al., Virol., 43:623-628 (1971)); and
- (ix) mutations that disrupt or modify the correct cell cycle, such as minB (de Boer et al., Cell, 56:641-649 (1989)) mutation.
- The attenuating mutations can be either constitutively expressed or under the control of inducible promoters, such as the temperature sensitive heat shock family of promoters (Neidhardt et al., 1984, supra), or the anaerobically induced nirB promoter (Harborne et al., Mol. Micro., 6:2805-2813 (1992)) or repressible promoters, such as uapA (Gorfinkiel et al., J. Biol. Chem., 268:23376-23381 (1993)) or gcv (Stauffer et al., J. Bact., 176:6159-6164 (1994)).
- The particular naturally occurring invasive bacteria (or attenuated, invasive bacteria) employed in the present invention is not critical thereto. One of ordinary skill in the art can readily determine which bacterial strains are appropriate for use with the animal or animal cells intended to be infected based on the animal's or cells' susceptibility to infection by different bacterial species. Examples of such naturally-occurring invasive bacteria include, but are not limited to, Salmonella spp. Shigella spp., Listeria spp., Rickettsia spp. and enteroinvasiveEscherichia coli. Any of these strains can be attenuated if needed using known methods.
- Examples of Shigella strains which can be employed in the present invention include, but are not limited to,Shigella flexneri 2a (ATCC No. 29903), Shigella sonnei (ATCC No. 29930), and Shigella disenteriae (ATCC No. 13313). An attenuated Shigella strain, such as Shigella flexneri 2a 2457T Δ aroA Δ virG mutant CVD 1203 (Noriega et al., supra), Shigella flexneri M90T Δ icsA mutant (Goldberg et al., Infect. Immun., 62:5664-5668 (1994)), Shigella flexneri Y SFL114 aroD mutant (Karnell et al., Vacc., 10:167-174 (1992)), and Shigella flexneri Δ aroA Δ aroD mutant (Verma et al., Vacc., 9:6-9 (1991)) are preferably employed in the present invention. Alternatively, new attenuated Shigella spp. strains can be constructed by introducing an attenuating mutation either singularly or in conjunction with one or more additional attenuating mutations.
- Examples of Listeria strains which can be employed in the present invention includeListeria monocytogenes (ATCC No. 15313). Attenuated Listeria strains, such as L. monocytogenes Δ actA mutant (Brundage et al., supra) or L. monocytogenes Δ plcA (Camilli et al., J. Exp. Med., 173:751-754 (1991)) are preferably used in the present invention. Alternatively, new attenuated Listeria strains can be constructed by introducing one or more attenuating mutations as described for Shigella spp. above.
- Examples of Rickettsia strains which can be employed in the present invention includeRicketsia rickettsiae (ATCC Nos. VR149 and VR891), Ricketsia prowaseckii (ATCC No. VR233), Ricketsia tsutsugamuchi (ATCC Nos. VR312, VR150 and VR609), Ricketsia mooseri (ATCC No. VR144), Ricketsia sibirica (ATCC No. VR151), and Rochalimaea quitana (ATCC No. VR358). Attenuated Ricketsia strains are preferably used in the present invention and can be constructed by introducing one or more attenuating mutations as described for Shigella spp. above.
- Examples of enteroinvasive Escherichia strains which can be employed in the present invention includeEscherichia coli strains 4608-58, 1184-68, 53638-C-17, 13-80, and 6-81 (Sansonetti et aL, Ann. Microbiol. (Inst. Pasteur), 132A:351-355 (1982)). Attenuated enteroinvasive Escherichia strains are preferably used in the present invention and can be constructed by introducing one or more attenuating mutations as described for Shigella spp. above.
- Examples of Salmonella strains which can be employed in the present invention includeSalmonella typhi (ATCC No. 7251) and S. typhimurium (ATCC No. 13311). Attenuated Salmonella strains are preferably used in the present invention and include S. typhi aroAaroD (Hone et al., Vacc., 9:810-816 (1991)) and S. typhimurium aroA mutant (Mastroeni et al., Micro. Pathol., 13:477-491 (1992))). Alternatively, new attenuated Salmonella strains can be constructed by introducing one or more attenuating mutations as described for Shigella spp. above.
- Examples of additional bacteria which can be genetically engineered to be invasive include, but are not limited to, Yersinia spp., Escherichia spp., Klebsiella spp., Bordetella spp., Neisseria spp., Aeromonas spp., Franciesella spp., Corynebacterium spp., Citrobacter spp., Chlamydia spp., Hemophilus spp., Brucella spp., Mycobacterium spp., Legionella spp., Rhodococcus spp., Pseudomonas spp., Helicobacter spp., Salmonella spp., Vibrio spp., Bacillus spp., and Erysipelothrix spp. These organisms can be engineered to mimic the invasion properties of Shigella spp., Listeria spp., Rickettsia spp., or enteroinvasiveE. coli spp. by inserting genes that enable them to access the cytoplasm of an animal cell. Examples of useful strains from these bacteria are found in U.S. Pat. No. 5,877,159 and also include Mycobacterium bovis BCG.
- Examples of such genes include the invasive proteins of Shigella, hemolysin or the invasion plasmid of Escherichia, or listeriolysin O of Listeria, as such techniques are known to result in strains that are capable of entering the cytoplasm of infected animal cells (Formal etal., Infect. immun., 46:465 (1984); Bielecke etal., Nature, 345:175-176 (1990); Small et al., In: Microbiology-1986, pages 121-124, Levine et al., Eds., American Society for Microbiology, Washington, D.C. (1986); and Zychlinsky et al., Molec. Micro., 11:619-627 (1994)). Any gene or combination of genes, from one or more sources, that mediates entry into the cytoplasm of animal cells will suffice. Thus, such genes are not limited to bacterial genes, and include viral genes, such as influenza virus hemagglutinin HA-2 which promotes endosmolysis (Plank et al., J. Biol. Chem., 269:12918-12924 (1994)).
- The above invasive genes can be introduced into the target strain using chromosome or plasmid mobilization (Miller, A Short Course in Bacterial Genetics, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1992); Bothwell et al., supra; and Ausubel et al., supra), bacteriophage-mediated transduction (de Boer, supra; Miller, supra; and Ausubel et al., supra), or chemical (Bothwell et al., supra; Ausubel et al., supra; Felgner et al., supra; and Farhood, supra), electroporation (Bothwel et al., supra; Ausubel et al., supra; and Sambrook, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.) and physical transformation techniques (Johnston et al., supra; and Bothwell, supra). The genes can be incorporated on bacteriophage (de Boer et al., Cell, 56:641-649 (1989)), plasmids vectors (Curtiss et al., supra) or spliced into the chromosome (Hone et al., supra) of the target strain.
- Furthermore, the bacteria for use in the invention can be modified to increase their ability to infect mucosal surfaces and tissues in an animal Such modifications permit the bacteria to circumvent natural host barriers. Methods for constructing such bacteria are described in U.S. Pat. No. 5,877,159.
- In accordance with the invention the invasive or attenuated invasive bacteria contain a DNA comprising a eukaryotic expression cassette operably linked to an alphavirus replicon DNA. A eukaryotic expression cassette is usually in the form of a plasmid which contains elements needed for transcription of the alphavirus replicon DNA and transport from the nucleus into the cytoplasm. For example, RNA polymerase II cassettes provide the needed control and regulatory elements. Hence, the elements for transcription include but are not limited to promoters active in eukaryotic cells, enhancers, transcription termination signals including polyadenylation signals or polyA tracts, elements to facilitate nucleocytoplasmic transport, elements to facilitate processing of the3′ alphavirus replicon RNA into an authentic virus-like RNA 3′ ends and the like.
- Hence, the particular eukaryotic cassette employed in the present invention is not critical thereto, and can be selected from, e.g., any of the many commercially available cassettes, such as pCEP4 or pRc/RSV obtained from Invitrogen Corporation (San Diego, Calif.), pXT1, pSG5, pPbac or pMbac obtained from Stratagene (La Jolla, Calif.), pPUR or pMAM obtained from ClonTech (Palo Alto, Calif.), and pSV.beta.-gal obtained from Promega Corporation (Madison, Wis.), or synthesized either de novo or by adaptation of a publically or commercially available eukaryotic expression system.
- The individual elements within the eukaryotic expression cassette can be derived from multiple sources and may be selected to confer specificity in sites of action or longevity of the cassettes in the recipient cell. Such manipulation of the eukaryotic expression cassette can be done by any standard molecular biology approach.
- Various promoters well-known to be useful for driving expression of genes in animal cells, such as the viral-derived SV40, CMV immediate early and, RSV promoters or eukaryotic derived β-casein, uteroglobin, β-actin or tyrosinase promoters. The particular promoter is not critical to the invention, unless the object is to obtain tissue-specific expression. In this case, the promoter can be selected which is only active in the desired tissue or selected cell type. Examples of tissue-specific promoters include, but are not limited to, αS1- and β-casein promoters which are specific for mammary tissue (Platenburg et al., Trans. Res., 3:99-108 (1994); and Maga et al., Trans. Res., 3:36-42 (1994)); the phosphoenolpyruvate carboxykinase promoter which is active in liver, kidney, adipose, jejunum and mammary tissue (McGrane et al., J. Reprod. Fert., 41:17-23 (1990)); the tyrosinase promoter which is active in lung and spleen cells, but not testes, brain, heart, liver or kidney (Vile et al., Canc. Res., 54:6228-6234 (1994)); the involucerin promoter which is only active in differentiating keratinocytes of the squamous epithelia (Carroll et al., J. Cell Sci., 103:925-930 (1992)); and the uteroglobin promoter which is active in lung and endometrium (Helftenbein et al., Annal. N.Y. Acad. Sci., 622:69-79 (1991)).
- Alternatively, cell specific enhancer sequences can be used to control expression, for example human neurotropic papovirus JCV enhancer regulates viral transcription in glial cells alone (Remenick et al., J. Virol., 65:5641-5646 (1991)). Yet another way to control tissue specific expression is to use a hormone responsive element (HRE) to specify which cell lineages a promoter will be active in, for example, the MMTV promoter requires the binding of a hormone receptor, such as progesterone receptor, to an upstream HRE before it is activated (Beato, FASEB J., 5:2044-2051 (1991); and Truss et al., J. Steroid Biochem. Mol. Biol., 41:241-248 (1992)).
- Suitable transcription termination elements include the SV 40 transcription termination region and terminators derived therefrom.
- Additional examples of eukaryotic expression cassettes and/or regulatory elements suitable for expressing alphavirus replicon DNA are described in U.S. Pat. Nos. 5,824,538 and 5,877,159.
- The bacteria of the bacterial delivery systems can contain one or more eukaryotic expression cassettes operably linked to an alphavirus replicon. Such cassettes can be provided on the same or different plasmids or DNA molecules contained in the bacteria. For example, in some instances it may be desirable for the eukaryotic expression cassette to be integrated into the bacterial chromosome or other episomal DNA.
- Alphavirus are from the Togavirus family and are well known in the art. There are 26 known viruses and virus subtype classified using the hemagglutination assay. See, e.g., U.S. Pat. No. 5,843,723 for list of the many of the alphaviruses. The commonly studied alphaviruses include Sindbis, SFV, Venezuelan equine encephalitis virus (VEE) and Ross River virus. The morphogenesis of the viruses is fairly uniform and the virions are small enveloped 60-65 nm particles of positive strand RNA. The genomic RNA (49S RNA) of alphaviruses is approximately 11-12 kb in length, and contains a 5′ cap and a 3′ polyadenylate tail. Infectious enveloped virus is produced by assembly of the viral nucleocapsid proteins onto genomic RNA in the cytoplasm, and budding through the cell membrane embedded with viral-encoded glycoproteins. During viral replication, the genomic 49S RNA serves as template for synthesis of a complementary negative strand. The negative strand in turn serves as template for full-length genomic RNA and for an internally initiated positive-strand 26S subgenomic RNA. The nonstructural proteins are translated from the genomic RNA. Alphaviral structural proteins are translated from the subgenomic 26S RNA. All viral genes are expressed as polyproteins and processed into individual proteins by proteolytic cleavage post-translation.
- As used herein, an “alphavirus replicon” of the present invention is used interchangeably to refer to RNA or DNA comprising those portions of the alphavirus genome RNA essential for transcription and export of a primary RNA transcript from the cell nucleus to the cytoplasm, for cytoplasmic amplification of the transported RNA and for subgenomic RNA expression of a heterologous nucleic acid sequence. Thus, the replicon encodes and expresses those non-structural proteins needed for cytoplasmic amplification of the alphavirus RNA and expression of the subgenomic RNA. It is further preferable that the alphavirus replicon can not be encapsidated to produce alphavirus particles or virions. This is achieved in replicons which lack one or more of the alphavirus structural genes, and preferably all of the structural genes. In a preferred embodiment, alphavirus replicons of the invention are capable of being transcribed from a eukaryotic expression cassette and processed into RNA molecules with authentic alphavirus-like 5′ and 3′ ends.
- Alphavirus replicons and expression vectors containing them are well known in the art and many vectors containing a wide range of alphavirus replicons have been described. Examples of such replicons can be found, e.g., in U.S. Pat. Nos. 5,739,026; 5,766,602; 5,789,245; 5,792,462; 5,814,482; and 5,843,723 and in Polo, supra, and Berglund, supra. While many of the features of these alphavirus replicons are useful for the present invention not all of them are essential for the reasons set forth above. So long as a portion of the alphavirus replicon does not interfere with production of the primary RNA, cytoplasmic amplification thereof and expression of the heterologous nucleic acid sequence, such portions can remain as part of the replicon. Those skilled in the art can readily determine the nature of and remove any unnecessary or interfering sequences.
- The patents and references set forth above also describe representative methods for constructing and producing the alphavirus replicons of the inventions. Alphavirus replicons can be prepared from any alphavirus or any mixture of alphavirus nucleic acid sequences. In this regard the preferred alphavirus replicons are derived from Sindbis virus, SFV, VEE or Ross River virus.
- The alphavirus replicons can be incorporated as DNA into eukaryotic expression cassettes using recombinant DNA techniques conventional in the art.
- In accordance with the invention, the alphavirus replicon comprises a nucleic acid sequence operably linked to a heterologous nucleic acid sequence to control expression thereof. The heterologous nucleic acid sequence can encode an antigen, an antigenic fragment of a protein, a therapeutic agent, an immunoregulatory agent, an anti-sense RNA, a catalytic RNA, a protein, a peptide or any other molecule encodable by DNA and desired for delivery to an animal or animal cell. The heterologous nucleic acid sequences can be obtained from a virus selected from the group consisting of influenza virus, respiratory syncytial virus, HPV, HBV, HCV, HIV, HSV, FeLV, FIV, HTLV-I, HTLV-II, and CMV. Such viral sequences can encode one or more viral genes or antigenic fragments thereof. The heterologous nucleotide sequence can also encode a cytokine, an interleukin, erythropoietin or other immunostimulatory or immunoregulatory protein.
- As used herein, heterologous refers to the relationship between the source of the alphavirus replicon and the source of the heterologous nucleic acid sequence. Thus, the heterologous nucleic acid gene will not be encode an alphavirus gene but could encode a gene that is either foreign or endogenous to the animal cells that have been infected with the bacterial delivery system of the invention. As used herein, “foreign gene or nucleic acid sequence” means a gene or a nucleic acid sequence encoding a protein or fragment thereof or anti-sense RNA or catalytic RNA, which is foreign to the recipient animal cell or tissue, such as a vaccine antigen, immunoregulatory agent, or therapeutic agent. An “endogenous gene or nucleic acid sequence” means a gene or a nucleic acid sequence encoding a protein or part thereof or anti-sense RNA or catalytic RNA which is naturally present in the recipient animal cell or tissue.
- The antigen may be a protein or antigenic fragment thereof from viral pathogens, bacterial pathogens, and parasitic pathogens. Alternatively, the antigen may be a synthetic gene, constructed using recombinant DNA methods, which encode antigens or parts thereof from viral, bacterial, parasitic pathogens. These pathogens can be infectious in humans, domestic animals or wild animal hosts.
- The antigen can be any molecule that is expressed by any viral, bacterial, parasitic pathogen prior to or during entry into, colonization of, or replication in their animal host.
- Single or multiple eukaryotic expression cassettes can be delivered that express any combination of viral, bacterial, parasitic antigens, or synthetic genes encoding all or parts or any combination of viral, bacterial, parasitic antigens.
- The viral pathogens, from which the viral antigens are derived, include, but are not limited to, Orthomyxoviruses, such as influenza virus; Retroviruses, such as RSV and SIV, Herpesviruses, such as EBV; CMV orherpes simplex virus; Lentiviruses, such as human immunodeficiency virus; Rhabdoviruses, such as rabies; Picornoviruses, such as poliovirus; Poxviruses, such as vaccinia; Rotavirus; and Parvoviruses. Examples of protective antigens of viral pathogens include the HIV antigens Nef, p24, gp 120, gp41, gp 160, Tat, Rev, and Pol et al., Nature, 313:277-280 (1985)) and T cell and B cell epitopes of gp120 (Palker et al., J. Immunol., 142:3612-3619 (1989)); the hepatitis B surface antigen (Wu et al., Proc. Natl. Acad. Sci., USA, 86:4726-4730 (1989)); rotavirus antigens, such as VP4 (Mackow et al., Proc. Natl. Acad. Sci., USA, 87:518-522 (1990)) and VP7 (Green et al., J. Virol., 62:1819-1823 (1988)), influenza virus antigens such as hemagglutinin or nucleoprotein (Robinson et al.., Supra; Webster et al., Supra) and herpes simplex virus thymidine kinase (Whitley et al., In: New Generation Vaccines, pages 825-854). In the case of HIV the antigens can be from any structural, accessory or regulatory gene, and includes combinations or chimeras of such genes in multiple or single alphavirus replicons.
- The bacterial pathogens, from which the bacterial antigens are derived, include but are not limited to, Mycobacterium spp.,Helicobacter pylori, Salmonella spp., Shigella spp., E. coli, Rickettsia spp., Listeria spp., Legionella pneumoniae, Pseudomonas spp., Vibrio spp., and Borellia burgdorferi.
- Examples of protective antigens of bacterial pathogens include theShigella sonnei form 1 antigen (Formal et al., Infect. Immun., 34:746-750 (1981)); the O-antigen of V. cholerae Inaba strain 569B (Forrest et al., J. Infect. Dis., 159:145-146 (1989); protective antigens of enterotoxigenic E. coli, such as the CFA/I fimbrial antigen (Yamamoto et al., Infect. Immun., 50:925-928 (1985)) and the nontoxic B-subunit of the heat-labile toxin (Clements et al., 46:564-569 (1984)); pertactin of Bordetella pertussis (Roberts et al., Vacc., 10:43-48 (1992)), adenylate cyclase-hemolysin of B. pertussis (Guiso et al., Micro. Path., 11:423-431 (1991)), and fragment C of tetanus toxin of Clostridium tetani (Fairweather et al., Infect. Immun., 58:1323-1326 (1990)).
- The parasitic pathogens, from which the parasitic antigens are derived, include but are not limited to, Plasmodium spp., Trypanosome spp., Giardia spp., Boophilus spp., Babesia spp., Entamoeba spp., Eimeria spp., Leishmania spp., Schistosome spp., Brugia spp., Fascida spp., Dirofilaria spp., Wuchereria spp., and Onchocerea spp.
- Examples of protective antigens of parasitic pathogens include the circumsporozoite antigens of Plasmodium spp. (Sadoff et al., Science, 240:336-337 (1988)), such as the circumsporozoite antigen ofP. bergerii or the circumsporozoite antigen of P. falciparum; the merozoite surface antigen of Plasmodium spp. (Spetzler et al., Int. J. Pept. Prot. Res., 43:351-358 (1994)); the galactose specific lectin of Entamoeba histolytica (Mann et al., Proc. Natl. Acad. Sci., USA, 88:3248-3252 (1991)), gp63 of Leishmania spp. (Russell et al., J. Immunol., 140:1274-1278 (1988)), paramyosin of Brugia malayi (Li et al., Mol. Biochem. Parasitol., 49:315-323 (1991)), the triose-phosphate isomerase of Schistosoma mansoni (Shoemaker et al., Proc. Natl. Acad. Sci., USA, 89:1842-1846 (1992)); the secreted globin-like protein of Trichostrongylus colubriformis (Frenkel et al., Mol. Biochem. Parasitol., 50:27-36 (1992)); the glutathione-S-transferase's of Frasciola hepatica (Hillyer et al., Exp. Parasitol., 75:176-186 (1992)), Schistosoma bovis and S. japonicum (Bashir et al., Trop. Geog. Med., 46:255-258 (1994)); and KLH of Schistosoma bovis and S. japonicum (Bashir et al., supra).
- In the present invention, the live invasive bacteria can also deliver eukaryotic expression cassettes encoding a therapeutic agent to animal cells or animal tissue. For example, the eukaryotic expression cassettes can encode tumor-specific, transplant, or autoimmune antigens or parts thereof. Alternatively, the eukaryotic expression cassettes can encode synthetic genes, which encode tumor-specific, transplant, or autoimmune antigens or parts thereof. Examples of tumor specific antigens include prostate specific antigen (Gattuso et al., Human Pathol., 26:123-126 (1995)), TAG-72 and CEA (Guadagni et al., Int. J. Biol. Markers, 9:53-60 (1994)), MAGE-1 and tyrosinase (Coulie et al., J. Immunothera., 14:104-109 (1993)). Recently it has been shown in mice that immunization with non-malignant cells expressing a tumor antigen provides a vaccine effect, and also helps the animal mount an immune response to clear malignant tumor cells displaying the same antigen (Koeppen et al., Anal. N.Y. Acad. Sci., 690:244-255 (1993)). Examples of transplant antigens include the CD3 receptor on T cells (Alegre et al., Digest. Dis. Sci., 40:58-64 (1995)). Treatment with an antibody to CD3 receptor has been shown to rapidly clear circulating T cells and reverse most rejection episodes (Alegre et al., supra). Examples of autoimmune antigens include IAS .beta. chain (Topham et al., Proc. Natl. Acad. Sci., USA, 91:8005-8009 (1994)). Vaccination of mice with an 18 amino acid peptide from IAS beta. chain has been demonstrated to provide protection and treatment to mice with experimental autoimmune encephalomyelitis (Topham et al., supra).
- Alternatively, in the present invention, live invasive bacteria can deliver eukaryotic expression cassettes encoding immunoregulatory molecules. These immunoregulatory molecules include, but are not limited to, growth factors, such as M-CSF, GM-CSF; and cytokines, such as IL-2, IL-4, L-5, IL-6, IL-10, IL-12 or IFN-gamma. Recently, delivery of cytokines expression cassettes to tumor tissue has been shown to stimulate potent systemic immunity and enhanced tumor antigen presentation without producing a systemic cytokine toxicity (Golumbek et al., Canc. Res., 53:5841-5844 (1993); Golumbek et al., Immun. Res., 12:183-192 (1993); Pardoll, Curr. Opin. Oncol., 4:1124-1129 (1992); and Pardoll, Curr. Opin. Immunol., 4:619-623 (1992)).
- The antisense RNA and catalytic RNA species delivered to animal cells can be targeted against any molecule present within the recipient cell or likely to be present within the recipient cell. These include but are not limited to RNA species encoding cell regulatory molecules, such as interleukin-6 (Mahieu et al., Blood, 84:3758-3765 (1994)), oncogenes such as ras (Kashani-Sabet et al., Antisen. Res. Devel., 2:3-15 (1992)), causative agents of cancer such as human papillomavirus (Steele et al., Canc. Res., 52:4706-4711 (1992)), enzymes, viral RNA's and pathogen derived RNA's such as HIV-1 (Meyer et al., Gene, 129:263-268 (1993); Chatterjee et al., Sci., 258:1485-1488 (1992); and Yamada et al., Virol., 205:121-126 (1994)). The RNAs can also be targeted at non-transcribed DNA sequences, such as promoter or enhancer regions, or to any other molecule present in the recipient cells, such as but not limited to, enzymes involved in DNA synthesis or tRNA molecules (Scanlon et al., Proc. Natl. Acad. Sci. USA, 88:10591-10595 (1991); and Baier et al., Mol. Immunol., 31:923-932 (1994)).
- In the present invention, live invasive bacteria can also deliver eukaryotic expression cassettes encoding proteins to animal tissue from which they can later be harvested or purified. An example is the delivery of a eukaryotic expression cassette under the control of a mammary specific viral promoter, such as derived from mouse mammary tumor virus (ATCC No. VR731), encoding α-antitrypsin to mammary tissue of a goat or sheep.
- Alternatively an invasive bacteria carrying a eukaryotic expression cassette can be introduced to a tissue site such that it would not spread from such a site. This could be accomplished by any of several methods including delivery of a very limited dose, delivery of a severely attenuated auxotrophic strain, such as an asd mutant (Curtiss et al., supra) that will be rapidly inactivated or die, or delivery of a bacterial strain that contains attenuating lesions, such as a suicide systems (Rennell et al., supra; and Reader et al., supra) under the control of a strong promoter, such as the anaerobic nirB promoter (Harborne et al., supra) which will be switched on within the recipient host tissue. Additionally, through use of different species and/or serotypes multiple doses of invasive bacteria, the eukaryotic expression cassette of interest can be given to an animal so as to manipulate expression levels or product type. This approach obviates the need for specially raised transgenic animals containing tissue specific promoters and having tight control of expression, as is currently the case (Janne et al., Int. J. Biochem., 26:859-870 (1994); Mullins et al., Hyperten., 22:630-633 (1993); and Persuy et al., Eur. J. Bichem., 205:887-893 (1992)).
- As a further alternative, single or multiple eukaryotic expression cassettes encoding tumor-specific, transplant, and/or autoimmune antigens, can be delivered in any single or multiple combination with eukaryotic expression cassettes encoding immunoregulatory molecules or other proteins.
- The invasive bacteria containing the eukaryotic expression cassette can be used to infect animal cells that are cultured in vitro. The animal cells can be further cultured in vitro, and the cells carrying the desired genetic trait can be enriched by selection for or against any selectable marker introduced to the recipient cell at the time of bactofection. Such markers may include antibiotic resistance genes, e.g., hygromycin, or neomycin, selectable cell surface markers, or any other phenotypic or genotypic element introduced or altered by bactofection. These in vitro-infected cells or the in vitro-enriched cells can then be introduced into animals intravenously, intramuscularly, intradermally, or intraperitoneally, or by any inoculation route that allows the cells to enter the host tissue.
- Alternatively, the invasive (or invasive, attenuated) bacteria containing the eukaryotic expression cassettes can be introduced to infect the animal by intravenous, intramuscular, intradermal, intraperitoneally, peroral, intranasal, intraocular, intrarectal, intravaginal, oral, immersion and intraurethral inoculation routes.
- The amount of the live invasive (or invasive, attenuated) bacteria of the present invention to be administered will vary depending on the species of the subject, as well as the disease or condition that is being treated. Generally, the dosage employed will be about 103 to 1011 viable organisms, preferably about 105 to 109 viable organisms. Alternatively, when bactofecting individual cells, the dosage of viable organisms to administered will be at a multiplicity of infection ranging from about 0.1 to 106, preferably about 102 to 104.
- The invasive bacteria of the present invention are generally administered along with a pharmaceutically acceptable carrier or diluent.
- The particular pharmaceutically acceptable carrier or diluent employed is not critical to the present invention. Examples of diluents include a phosphate buffered saline, buffer for buffering against gastric acid in the stomach, such as citrate buffer (pH 7.0) containing sucrose, bicarbonate buffer (pH 7.0) alone (Levine et al., J. Clin. Invest., 79:888-902 (1987); and Black et al. J. Infect. Dis., 155:1260-1265 (1987)), or bicarbonate buffer (pH 7.0) containing ascorbic acid, lactose, and optionally aspartame (Levine et al., Lancet, II:467-470 (1988)). Examples of carriers include proteins, e.g., as found in skim milk, sugars, e.g., sucrose, or polyvinylpyrrolidone. Typically these carriers would be used at a concentration of about 0.1-90% (w/v) but preferably at a range of 1-10% (w/v).
- When infecting animal cells, the methods of the invention can be used in mammalian, avian, insect cells and the like. Preferably the mammalian cells are selected from the group consisting of human, bovine, ovine, porcine, feline, buffalo, canine, goat, equine, donkey, deer, and primate cells.
- When infecting animals, the methods of the invention are preferably used in mammals and birds. The preferred mammal is a human.
Claims (58)
1. A bacterial delivery system which comprises live, attenuated invasive Salmonella bacteria containing a DNA comprising a eukaryotic expression cassette operably linked to an alphavirus replicon DNA capable of amplification as RNA in animal cells, wherein the alphavirus replicon DNA comprises at least one nucleic acid control sequence operably linked to a heterologous nucleic acid sequence to control expression of said heterologous genes.
2. The bacterial delivery system of claim 1 , wherein said Salmonella is Salmonella typhi.
3. The bacterial delivery system of claim 2 , wherein said bacteria are attenuated via an attenuating mutation in an aro gene, an asd gene, an htrA gene or in a combination of one or more of these genes.
4. The bacterial delivery system of claim 3 , wherein said bacteria have an attenuating mutation in an aro gene and an asd gene.
5. The bacterial delivery system of claim 4 , wherein said aro gene is aroA and/or aroD.
6. The bacterial delivery system of claim 3 , wherein said bacteria have an attenuating mutation in an aro gene and an htrA gene.
7. The bacterial delivery system of claim 6 , wherein said aro gene is aroA and/or aroD.
8. The bacterial delivery system of claim 1 , wherein said heterologous nucleic acid sequence comprises one or more coding regions of a gene and wherein each coding region of said heterologous nucleic acid sequence can be expressed separately or as an operon.
9. The bacterial delivery system of claim 8 , wherein said heterologous nucleic acid sequence encodes an antigen or an antigenic fragment of a protein from a viral pathogen.
10. The bacterial delivery system of claim 9 , wherein said viral pathogen is HIV.
11. The bacterial delivery system of any one of claims 1-8, wherein said heterologous nucleic acid sequence encodes one or more HIV genes selected from the group consisting of env, gag, pol, or an antigenic fragment of a protein encoded by any one of said genes, wherein said genes are from an HIV isolate and/or from a consensus sequence of HIV isolates.
12. The bacterial delivery system of claim 11 , wherein said heterologous nucleic acid sequence encodes at least one antigen or antigenic fragment from each of the HIV genes env, gag, pol, nef, tat, and rev.
13. A method for introducing and expressing a gene in an animal which comprises infecting said animal with the bacterial delivery system of claim 11 , and thereby obtaining expression of a gene product encoded by said heterologous nucleic acid sequence in said animal.
14. The method of claim 13 wherein infecting occurs by an intranasal delivery route.
15. A method for inducing an immune response in an animal which comprises infecting said animal with live, attenuated invasive Salmonella bacteria containing a DNA comprising a eukaryotic expression cassette operably linked to an alphavirus replicon DNA capable of amplification as RNA in animal cells, wherein the alphavirus replicon DNA encodes at least one antigen or antigenic fragment of a protein, and wherein said antigen or said fragment is expressed at a level sufficient to stimulate an immune response to said antigen or said fragment.
16. The method of claim 15 , wherein said Salmonella is Salmonella typhi.
17. The method of claim 16 , wherein said bacteria are attenuated via an attenuating mutation in an aro gene, an asd gene, an htrA gene or in a combination of one or more of these genes.
18. The method of claim 17 , wherein said bacteria have an attenuating mutation in an aro gene and an asd gene.
19. The method of claim 18 , wherein said aro gene is aroA and/or aroD.
20. The method of claim 17 , wherein said bacteria have an attenuating mutation in an aro gene and an htrA gene.
21. The method of claim 20 , wherein said aro gene is aroA and/or aroD.
22. The method of claim 15 , wherein said antigen or said antigenic fragment is a tumor antigen, a transplantation antigen or an autoimmune antigen.
23. The method of any one of claims 15-21, wherein said antigen or said antigenic fragment of a protein is from a viral pathogen, a bacterial pathogen or a parasitic pathogen.
24. The method of claim 23 , wherein said viral pathogen is HIV.
25. The method of any one of claims 15-21, wherein said antigen or antigenic fragment is encoded by one or more HIV genes selected from the group consisting of env, gag, pol, nef, tat, or rev, wherein said HIV genes are from an HIV isolate and/or from a consensus sequence of HIV isolates.
26. The method of claim 25 , wherein said alphavirus replicon DNA encodes at least one antigen or antigenic fragment from each of the HIV genes env, gag, pol, nef, tat, and rev.
27. The method of any one of claims 15-21, wherein infecting occurs by an intranasal delivery route.
28. The method of claim 25 , wherein infecting occurs by an intranasal delivery route.
29. The method of claim 26 , wherein infecting occurs by an intranasal delivery route.
30. A bacterial delivery system which comprises live, attenuated invasive Shigella bacteria containing a DNA comprising a eukaryotic expression cassette operably linked to an alphavirus replicon DNA capable of amplification as RNA in animal cells, wherein the alphavirus replicon DNA comprises at least one nucleic acid control sequence operably linked to a heterologous nucleic acid sequence to control expression of said heterologous genes.
31. The bacterial delivery system of claim 30 , wherein said Shigella is Shigella flexneri or Shigella flexneri 2a
32. The bacterial delivery system of claim 31 , wherein said bacteria are attenuated via an attenuating mutation in an aro gene, a gua gene, a virG gene or in a combination of one or more of these genes.
33. The bacterial delivery system of claim 32 , wherein said bacteria have an attenuating mutation in an aro gene and a virg gene.
34. The bacterial delivery system of claim 33 , wherein said aro gene is aroA and/or aroD.
35. The bacterial delivery system of claim 32 , wherein said bacteria have an attenuating mutation in a gua gene and a virG gene.
36. The bacterial delivery system of claim 35 , wherein said aro gene is aroA and/or aroD.
37. The bacterial delivery system of claim 30 , wherein said heterologous nucleic acid sequence comprises one or more coding regions of a gene and wherein each coding region of said heterologous nucleic acid sequence can be expressed separately or as an operon.
38. The bacterial delivery system of claim 37 , wherein said heterologous nucleic acid sequence encodes an antigen or an antigenic fragment of a protein from a viral pathogen, a bacterial pathogen or a parasitic pathogen.
39. The bacterial delivery system of claim 38 , wherein said viral pathogen is HIV.
40. The bacterial delivery system of any one of claims 30-37, wherein said heterologous nucleic acid sequence encodes one or more HIV genes selected from the group consisting of env, gag, pol, or an antigenic fragment of a protein encoded by any one of said genes, wherein said genes are from an HIV isolate AND/or from a consensus sequence of HIV isolates.
41. The bacterial delivery system of claim 40 , wherein said heterologous nucleic acid sequence encodes at least one antigen or antigenic fragment from each of the HIV genes env, gag, pol, nef, tat, and rev.
42. A method for introducing and expressing a gene in an animal which comprises infecting said animal with the bacterial delivery system of claim 40 , and thereby obtaining expression of a gene product encoded by said heterologous nucleic acid sequence in said animal.
43. The method of claim 42 , wherein infecting occurs by an intranasal delivery route.
44. A method for inducing an immune response in an animal which comprises infecting said animal with live, attenuated invasive Shigella bacteria containing a DNA comprising a eukaryotic expression cassette operably linked to an alphavirus replicon DNA capable of amplification as RNA in animal cells, wherein the alphavirus replicon DNA encodes at least one antigen or antigenic fragment of a protein, and wherein said antigen or said fragment is expressed at a level sufficient to stimulate an immune response to said antigen or said fragment.
45. The method of claim 44 , wherein said Shigella is Shigella flexneri or Shigella flexneri 2a.
46. The method of claim 45 , wherein said bacteria are attenuated via an attenuating mutation in an aro gene, a gua gene, a virG gene or in a combination of one or more of these genes.
47. The method of claim 46 , wherein said bacteria have an attenuating mutation in an aro gene and a virG gene.
48. The method of claim 47 , wherein said aro gene is aroA and/or aroD.
49. The method of claim 48 , wherein said bacteria have an attenuating mutation in a gua gene and a virG gene.
50. The method of claim 49 , wherein said aro gene is aroA and/or aroD.
51. The method of claim 44 , wherein said antigen or said antigenic fragment is a tumor antigen, a transplantation antigen or an autoimmune antigen.
52. The method of any one of claims 44-50, wherein said antigen or said antigenic fragment of a protein is from a viral pathogen, a bacterial pathogen or a parasitic pathogen.
53. The method of claim 52 , wherein said viral pathogen is HIV.
54. The method of claim of any one of claims 44-50, wherein said antigen or antigenic fragment is encoded by one or more HIV genes selected from the group consisting of env, gag, pol, nef, tat, or rev, wherein said HIV genes are from an HIV isolate and/or from a consensus sequence of HIV isolates.
55. The method of claim 54 , wherein said alphavirus replicon DNA encodes at least one antigen or antigenic fragment from each of the HIV genes env, gag, pol, nef, tat, and rev.
56. The method of any one of claims 44-50, wherein infecting occurs by an intranasal delivery route.
57. The method of claim 54 , wherein infecting occurs by an intranasal delivery route.
58. The method of claim 55 , wherein infecting occurs by an intranasal delivery route.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/357,095 US20030170211A1 (en) | 1999-10-26 | 2003-02-03 | Invasive bacterial vectors for expressing alphavirus replicons |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16144899P | 1999-10-26 | 1999-10-26 | |
US09/697,236 US6531313B1 (en) | 1999-10-26 | 2000-10-26 | Invasive bacterial vectors for expressing alphavirus replicons |
US10/357,095 US20030170211A1 (en) | 1999-10-26 | 2003-02-03 | Invasive bacterial vectors for expressing alphavirus replicons |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/697,236 Continuation US6531313B1 (en) | 1999-10-26 | 2000-10-26 | Invasive bacterial vectors for expressing alphavirus replicons |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030170211A1 true US20030170211A1 (en) | 2003-09-11 |
Family
ID=22581211
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/697,236 Expired - Fee Related US6531313B1 (en) | 1999-10-26 | 2000-10-26 | Invasive bacterial vectors for expressing alphavirus replicons |
US10/357,095 Abandoned US20030170211A1 (en) | 1999-10-26 | 2003-02-03 | Invasive bacterial vectors for expressing alphavirus replicons |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/697,236 Expired - Fee Related US6531313B1 (en) | 1999-10-26 | 2000-10-26 | Invasive bacterial vectors for expressing alphavirus replicons |
Country Status (9)
Country | Link |
---|---|
US (2) | US6531313B1 (en) |
EP (1) | EP1226263A1 (en) |
JP (1) | JP2003512077A (en) |
CN (1) | CN1413258A (en) |
AU (1) | AU784281B2 (en) |
CA (1) | CA2387921A1 (en) |
MX (1) | MXPA02004148A (en) |
WO (1) | WO2001031046A1 (en) |
ZA (1) | ZA200203096B (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050118193A1 (en) * | 2003-09-17 | 2005-06-02 | The Regents Of The University Of California | Bacterial vectors and methods of use thereof |
WO2006015445A1 (en) | 2004-08-13 | 2006-02-16 | Marshall Barry J | Bacterial delivery system |
US20060068469A1 (en) * | 2004-08-17 | 2006-03-30 | Research Development Foundation | Bacterial vector systems |
US20070134264A1 (en) * | 2004-08-13 | 2007-06-14 | Marshall Barry J | Helicobacter System And Uses Thereof |
US8841432B2 (en) * | 2011-04-21 | 2014-09-23 | Snu R&Db Foundation | Shuttle vectors for mycobacteria-escherichia coli and uses thereof |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
US10301379B2 (en) | 2014-06-26 | 2019-05-28 | Janssen Vaccines & Prevention B.V. | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
US10562963B2 (en) | 2014-06-26 | 2020-02-18 | Janssen Vaccines & Prevention, B.V. | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7045336B1 (en) * | 1995-09-06 | 2006-05-16 | The United States Of America As Represented By The Secretary Of The Army | Bacterial delivery system |
IT1304768B1 (en) * | 1998-10-05 | 2001-03-29 | Esaote Spa | TABLE FOR PATIENT HOLDER OR SIMILAR, AND MACHINE, IN PARTICULAR MACHINE FOR DETECTION OF IMAGES IN NUCLEAR MAGNETIC RESONANCE IN |
US20040033585A1 (en) | 2002-06-07 | 2004-02-19 | Mccormick Alison A. | Flexible vaccine assembly and vaccine delivery platform |
WO2005047483A2 (en) | 2003-11-12 | 2005-05-26 | Medical Research Council | Renta: an hiv immunogen and uses thereof |
DK1751289T3 (en) * | 2004-05-18 | 2009-05-11 | Alphavax Inc | TC-83-derived alphavirus vectors, particles and methods |
WO2011119920A2 (en) | 2010-03-25 | 2011-09-29 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
MX343037B (en) | 2011-04-06 | 2016-10-20 | Biovaxim Ltd | Pharmaceutical compositions for preventing and/or treating an hiv disease in humans. |
CA2832109C (en) | 2011-06-10 | 2021-07-06 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
CA2789539A1 (en) | 2011-09-12 | 2013-03-12 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
EP2586461A1 (en) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Viral particles derived from an enveloped virus |
ES2631608T3 (en) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Env-glycoprotein variant of HIV-1 |
US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
EP2873423B1 (en) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
CN113699184A (en) * | 2021-09-09 | 2021-11-26 | 中国科学院武汉病毒研究所 | VEEV expression vector suitable for expression of antibody and application |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5739026A (en) * | 1990-12-13 | 1998-04-14 | Bioption Ab | DNA expression systems based on alphaviruses |
US5766602A (en) * | 1993-02-08 | 1998-06-16 | Heska Corporation | Recombinant packaging defective Sindbis virus vaccines |
US5789245A (en) * | 1993-09-15 | 1998-08-04 | Chiron Corporation | Alphavirus structural protein expression cassettes |
US5792462A (en) * | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
US5824538A (en) * | 1995-09-06 | 1998-10-20 | The United States Of America As Represented By The Secretary Of The Army | Shigella vector for delivering DNA to a mammalian cell |
US5877159A (en) * | 1995-05-03 | 1999-03-02 | University Of Maryland At Baltimore | Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same |
US6500419B1 (en) * | 1997-10-07 | 2002-12-31 | University Of Maryland Biotechnology Institute | Method for introducing and expressing RNA in animal cells |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002515734A (en) | 1996-01-02 | 2002-05-28 | カイロン コーポレイション | Immunostimulation mediated by genetically modified dendritic cells |
-
2000
- 2000-10-26 CA CA002387921A patent/CA2387921A1/en not_active Abandoned
- 2000-10-26 AU AU13449/01A patent/AU784281B2/en not_active Ceased
- 2000-10-26 JP JP2001533181A patent/JP2003512077A/en active Pending
- 2000-10-26 CN CN00817758A patent/CN1413258A/en active Pending
- 2000-10-26 MX MXPA02004148A patent/MXPA02004148A/en active IP Right Grant
- 2000-10-26 US US09/697,236 patent/US6531313B1/en not_active Expired - Fee Related
- 2000-10-26 WO PCT/US2000/029465 patent/WO2001031046A1/en active Application Filing
- 2000-10-26 EP EP00975390A patent/EP1226263A1/en not_active Withdrawn
-
2002
- 2002-04-18 ZA ZA200203096A patent/ZA200203096B/en unknown
-
2003
- 2003-02-03 US US10/357,095 patent/US20030170211A1/en not_active Abandoned
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5739026A (en) * | 1990-12-13 | 1998-04-14 | Bioption Ab | DNA expression systems based on alphaviruses |
US5766602A (en) * | 1993-02-08 | 1998-06-16 | Heska Corporation | Recombinant packaging defective Sindbis virus vaccines |
US5789245A (en) * | 1993-09-15 | 1998-08-04 | Chiron Corporation | Alphavirus structural protein expression cassettes |
US5814482A (en) * | 1993-09-15 | 1998-09-29 | Dubensky, Jr.; Thomas W. | Eukaryotic layered vector initiation systems |
US5843723A (en) * | 1993-09-15 | 1998-12-01 | Chiron Corporation | Alphavirus vector constructs |
US5877159A (en) * | 1995-05-03 | 1999-03-02 | University Of Maryland At Baltimore | Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same |
US5792462A (en) * | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
US5824538A (en) * | 1995-09-06 | 1998-10-20 | The United States Of America As Represented By The Secretary Of The Army | Shigella vector for delivering DNA to a mammalian cell |
US6500419B1 (en) * | 1997-10-07 | 2002-12-31 | University Of Maryland Biotechnology Institute | Method for introducing and expressing RNA in animal cells |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7390646B2 (en) | 2003-09-17 | 2008-06-24 | The Regents Of The University Of California | Bacterial vectors and methods of use thereof |
US20050118193A1 (en) * | 2003-09-17 | 2005-06-02 | The Regents Of The University Of California | Bacterial vectors and methods of use thereof |
US8298806B2 (en) | 2004-08-13 | 2012-10-30 | Ondek Pty. Ltd. | Helicobacter system and uses thereof |
US20070134264A1 (en) * | 2004-08-13 | 2007-06-14 | Marshall Barry J | Helicobacter System And Uses Thereof |
US20060057152A1 (en) * | 2004-08-13 | 2006-03-16 | Marshall Barry J | Helicobacter system and uses thereof |
US20090220540A1 (en) * | 2004-08-13 | 2009-09-03 | Marshall Barry J | Helicobacter System and Uses Thereof |
US7968324B2 (en) | 2004-08-13 | 2011-06-28 | Barry J Marshall | Helicobacter system and uses thereof |
US8029777B2 (en) * | 2004-08-13 | 2011-10-04 | Marshall Barry J | Helicobacter system and uses thereof |
WO2006015445A1 (en) | 2004-08-13 | 2006-02-16 | Marshall Barry J | Bacterial delivery system |
US8298527B2 (en) | 2004-08-13 | 2012-10-30 | Ondek Pty. Ltd. | Helicobacter system and uses thereof |
US8420374B2 (en) | 2004-08-13 | 2013-04-16 | Ondek Pty. Ltd. | Helicobacter system and uses thereof |
US20060068469A1 (en) * | 2004-08-17 | 2006-03-30 | Research Development Foundation | Bacterial vector systems |
US8841432B2 (en) * | 2011-04-21 | 2014-09-23 | Snu R&Db Foundation | Shuttle vectors for mycobacteria-escherichia coli and uses thereof |
US10301379B2 (en) | 2014-06-26 | 2019-05-28 | Janssen Vaccines & Prevention B.V. | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
US10400034B2 (en) | 2014-06-26 | 2019-09-03 | Janssen Vaccines & Prevention, B.V. | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
US10562963B2 (en) | 2014-06-26 | 2020-02-18 | Janssen Vaccines & Prevention, B.V. | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
US11472869B2 (en) | 2014-06-26 | 2022-10-18 | Janssen Vaccines & Prevention B.V. | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
US11633435B1 (en) | 2014-09-18 | 2023-04-25 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
US10449237B1 (en) | 2014-09-18 | 2019-10-22 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
US10729731B1 (en) | 2014-09-18 | 2020-08-04 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
US10828356B1 (en) | 2014-09-18 | 2020-11-10 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
US11813295B1 (en) | 2014-09-18 | 2023-11-14 | Theobald Therapeutics LLC | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
US11406702B1 (en) | 2020-05-14 | 2022-08-09 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated Salmonella as a vaccine |
Also Published As
Publication number | Publication date |
---|---|
CN1413258A (en) | 2003-04-23 |
JP2003512077A (en) | 2003-04-02 |
MXPA02004148A (en) | 2003-08-20 |
ZA200203096B (en) | 2003-09-23 |
AU1344901A (en) | 2001-05-08 |
AU784281B2 (en) | 2006-03-02 |
EP1226263A1 (en) | 2002-07-31 |
CA2387921A1 (en) | 2001-05-03 |
WO2001031046A1 (en) | 2001-05-03 |
US6531313B1 (en) | 2003-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6531313B1 (en) | Invasive bacterial vectors for expressing alphavirus replicons | |
EP0827410B1 (en) | Method for introducing and expressing genes in animal cells | |
US6150170A (en) | Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same | |
US7393525B2 (en) | Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same | |
AU750106B2 (en) | Method for introducing and expressing RNA in animal cells | |
US7850958B2 (en) | Recombinant double stranded RNA nucleocapsid and use of the same | |
JP5665541B2 (en) | Methods for enhancing transgene expression from bacterial-based delivery systems by co-expression of eukaryotic type I interferon-responsive suppressors | |
US7125718B2 (en) | Method for introducing and expressing genes in animal cells, and bacterial blebs for use in same | |
US20080107683A1 (en) | Bacterial Packaging Strains Useful for Generation and Production of Recombinant Double-Stranded RNA Nucleocapsids and Uses Thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |